The use of next-generation sequencing (NGS) technologies to detect B-cell receptor (BCR) or T-cell receptor (TCR) clonotypes ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...
Chinese cell therapy company NewCure Biotech has raised more than 200 million yuan ($28 million) in a series B round to ...
Repertoire Immune Medicines partners with Eli Lilly to develop tolerizing therapies for autoimmune diseases, receiving $85 ...
Long-term protection against tumor recurrence in AMP-treated mice was associated with antigen spreading to additional tumor-associated antigens not targeted by the treatment Preclinical efficacy in ...
Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...
CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective against solid tumors. To fight such tumors, many groups have engineered T ...
Advances in cell and gene therapy have led to U.S. Food and Drug Administration approved adoptive cell therapies to treat hematological malignancies and solid tumors. There is great enthusiasm in the ...
Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a ...
Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers like lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results